Linked Life Data

18273830

Source:http://linkedlifedata.com/resource/pubmed/id/18273830

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2008-5-28
pubmed:abstractText
Excessive cigarette smoking and caffeine intake are often seen in schizophrenic patients being treated with antipsychotic drugs, particularly typical antipsychotic drugs. Using nicotine and caffeine sometimes influences psychotic symptoms in these patients. Clozapine is the only antipsychotic drug reported to reduce the amount of cigarette smoking, however, still remains controversial of its efficacy. In the present study, we examined the effect of acute risperidone treatment on the amount of cigarette smoking and plasma levels of cotinine and caffeine in schizophrenic patients. Treatment with risperidone for 4 weeks did not increase daily cigarette consumption or plasma levels of cotinine and caffeine. The results suggest that acute risperidone treatment does not promote the intake of nicotine and caffeine at least by 4 weeks in schizophrenic patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1099-1077
pubmed:author
pubmed:copyrightInfo
(c) 2008 John Wiley & Sons, Ltd.
pubmed:issnType
Electronic
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
327-32
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study.
pubmed:affiliation
Department of Psychiatry, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatansihi-ku, Kitakyushu, Fukuoka, Japan. yoshi621@med.uoeh-u.ac.jp
pubmed:publicationType
Journal Article